SCHEMBL3548210

SCHEMBL3548210

COc1cc(C(=S)Cl)cc(C(F)(F)F)c1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.44
LMNA P02545 5/20 0.44
GAA P10253 1/20 0.44
ALDH1A1 P00352 4/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP3A4 P08684 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
AURKA O14965 2/20 0.38
KDR P35968 2/20 0.38
AURKB Q96GD4 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HTT P42858 2/20 0.37
TPMT P51580 1/20 0.36
PTPN7 P35236 1/20 0.36
DUSP3 P51452 1/20 0.36
HPGD P15428 1/20 0.36
ALOX12 P18054 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3553864 0.85 ALDH1A1 (0.42) MAPTLMNAGAAALDH1A1MEN1
SCHEMBL3547712 0.84 MAPT (0.44) MAPTLMNAGAAALDH1A1MEN1
SCHEMBL3547245 0.79 SIRT1 (0.42) MAPTLMNAGAAALDH1A1MEN1
SCHEMBL3550251 0.78 PPARG (0.35) MAPTLMNAGAASMN1; SMN2PTPN7
SCHEMBL3553862 0.77 LMNA (0.47) MAPTLMNAGAAALDH1A1MEN1
SCHEMBL3547710 0.75 MAPT (0.49) MAPTLMNAGAAALDH1A1MEN1
SCHEMBL5204504 0.71 CYP3A4 (0.39) MAPTLMNAGAAALDH1A1MEN1
SCHEMBL5204242 0.70 ALDH1A1 (0.44) MAPTLMNAGAAALDH1A1MEN1
SCHEMBL10324062 0.69 GLRA1 (0.54) LMNAMEN1KMT2ASMN1; SMN2HPGD
SCHEMBL400758 0.68 NOTUM (0.43) MAPTLMNAGAAALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE MAPT 3703/4885LMNA 3400/4885GAA 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.